LX9211 not checked

Lexicon Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Diabetic Peripheral Neuropathy, Diabetes, Postherpetic Neuralgia, Diabetic Peripheral Neuropathic Pain
Main trialPhase 2
“Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.”In the company’s words, NCT04455633 on ClinicalTrials.gov

Other drugs for Diabetic Peripheral Neuropathy

All 227 drugs for Diabetic Peripheral Neuropathy

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Completed 23 May 2022 Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Phase 2Completed 18 Nov 2022 Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Phase 2Completed 14 Jan 2025 A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LX9211

Following is part of Solo: you see every change to LX9211 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in